Herpes simplex virus type-1(HSV-1) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in mice-4

Ved from a representative PBS-treated mouse.<p><b>Copyright information:</b></p><p>Taken from "Herpes simplex virus type-1(HSV-1) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in mice"</p><p>http://www.virologyj.com/content/5/1/68</p><p>Virology Journal 2008;5():68-68.</p><p>Published online 2 Jun 2008</p><p>PMCID:PMC2453120.</p><p></p

Herpes simplex virus type-1(HSV-1) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in mice-0

Rnal repeat (IR) regions. (b) Approximate locations of the gB and gK genes. (c) An expansion of the inverted repeat region showing the approximate locations of UL54, UL55, UL56, α 0, γ34.5, α 4, α 22 and US2 genes. (d) Schematic of the DNA fragment cloned into plasmid pJM-R, which was used for insertion of the HcRed gene cassette into the viral genome in place of the NV1020 genomic deletion as described in Materials and Methods.<p><b>Copyright information:</b></p><p>Taken from "Herpes simplex virus type-1(HSV-1) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in mice"</p><p>http://www.virologyj.com/content/5/1/68</p><p>Virology Journal 2008;5():68-68.</p><p>Published online 2 Jun 2008</p><p>PMCID:PMC2453120.</p><p></p

Herpes simplex virus type-1(HSV-1) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in mice-1

S were visualized 48 hr post infection by immunohistochemistry and photographed with a phase contrast microscope. Vero (g) and 4T1 (h) cells were infected with OncdSyn virus. Viral plaques were photographed 48 hr postinfection with a fluorescent microscope.<p><b>Copyright information:</b></p><p>Taken from "Herpes simplex virus type-1(HSV-1) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in mice"</p><p>http://www.virologyj.com/content/5/1/68</p><p>Virology Journal 2008;5():68-68.</p><p>Published online 2 Jun 2008</p><p>PMCID:PMC2453120.</p><p></p

Herpes simplex virus type-1(HSV-1) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in mice-5

Sentative stained sections are shown for PBS (c, d) and OncdSyn (e, f) groups at 40× (c, e) and 100× (d, f) magnifications. Metastatic foci are represented by arrows (c, d).<p><b>Copyright information:</b></p><p>Taken from "Herpes simplex virus type-1(HSV-1) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in mice"</p><p>http://www.virologyj.com/content/5/1/68</p><p>Virology Journal 2008;5():68-68.</p><p>Published online 2 Jun 2008</p><p>PMCID:PMC2453120.</p><p></p

Herpes simplex virus type-1(HSV-1) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in mice-3

Als prior and after treatment (x axis). Tumors were injected with either OncSyn, OncdSyn viruses, or PBS when tumors reached approximately 80–90 mmin volume. Tumor volumes were measured prior to (negative values on the x axis) and after the injections. "0" on X axis represents the day of the first injection. The tumor volumes were determined from the formula: volume = (length × width × height)/2. Arrows indicate the days when therapy was administered. The error bars represent means ± 2 standard errors. (b) Tumors were excised at 42 days post implantation and visually examined. Panel shows representative tumors from virus and PBS treated animals.<p><b>Copyright information:</b></p><p>Taken from "Herpes simplex virus type-1(HSV-1) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in mice"</p><p>http://www.virologyj.com/content/5/1/68</p><p>Virology Journal 2008;5():68-68.</p><p>Published online 2 Jun 2008</p><p>PMCID:PMC2453120.</p><p></p

Herpes simplex virus type-1(HSV-1) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in mice-6

Rnal repeat (IR) regions. (b) Approximate locations of the gB and gK genes. (c) An expansion of the inverted repeat region showing the approximate locations of UL54, UL55, UL56, α 0, γ34.5, α 4, α 22 and US2 genes. (d) Schematic of the DNA fragment cloned into plasmid pJM-R, which was used for insertion of the HcRed gene cassette into the viral genome in place of the NV1020 genomic deletion as described in Materials and Methods.<p><b>Copyright information:</b></p><p>Taken from "Herpes simplex virus type-1(HSV-1) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in mice"</p><p>http://www.virologyj.com/content/5/1/68</p><p>Virology Journal 2008;5():68-68.</p><p>Published online 2 Jun 2008</p><p>PMCID:PMC2453120.</p><p></p